期刊文献+

原发性抗磷脂综合征107例临床特点及血栓事件危险因素分析 被引量:30

The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome
原文传递
导出
摘要 目的 通过分析原发性抗磷脂综合征(APS)的临床特点,探讨原发性APS患者血栓栓塞事件的高危因素.方法 回顾性分析北京协和医院2004年1-12月住院治疗107例原发性APS患者的临床资料,包括临床表现、实验室检查、血栓形成部位,单因素和多因素logistic回归分析筛选静脉血栓事件和动脉血栓事件的危险因素.结果 72例(67.3%)患者出现静脉血栓事件,29例(27.1%)患者出现动脉血栓事件.静脉血栓事件最常见为深静脉血栓38例(35.5%),其次为肺血栓栓塞症32例(29.9%),颅内静脉窦血栓形成9例(8.4%).动脉血栓事件为短暂性脑缺血发作或缺血性卒中15例(14.0%),下肢动脉栓塞7例(6.5%),急性心肌梗死4例(3.7%).67例(62.6%)患者狼疮抗凝物阳性,60例(56.1%)患者抗心磷脂抗体阳性,32例(29.9%,32/74)患者抗β2糖蛋白I (β2GP I)抗体阳性.40例(37.4%)患者2个抗体(狼疮抗凝物和抗心磷脂抗体、狼疮抗凝物和抗β2GP I抗体、抗心磷脂抗体和抗β2GP I抗体)阳性,19例(17.8%)患者3个抗体(狼疮抗凝物、抗心磷脂抗体、抗β2GP I抗体)阳性.logistic回归分析显示,年龄(每增长10岁)(OR值为1.421,95% CI 1.066~1.894,P<0.05)、低补体血症(OR值为6.435,95%CI 1.374~30.130,P<0.05)是原发性APS患者出现静脉血栓事件的高危因素.吸烟(OR值3.996,95%CI 1.079~14.795,P<0.05)、3个抗体阳性(OR值为3.166,95% CI 1.102~9.097,P<0.05)是原发性APS出现动脉血栓事件的高危因素.结论 下肢深静脉血栓形成、肺栓塞、缺血性卒中/短暂性脑缺血发作是原发性APS最常见的静脉和动脉血栓事件;高龄、补体降低是原发性APS患者出现静脉血栓事件的高危因素,吸烟、3个抗体阳性是动脉血栓事件高危因素. Objective To investigate the clinical characteristics in patients with primary antiphospholipid syndrome (PAPS) and to identify potential predictors of thrombotic events.Methods A total of 107 patients with PAPS were enrolled in our study, who were admitted in Peking Union Medical College Hospital from January 2004 to December 2014.Demographic data, age at onset, disease duration, past history of hypertension and regular cigarette smoking, clinical manifestations, imaging characteristics, management and prognosis were retrospectively collected.Bivariate statistical analysis and logistical regression test were performed to compare the discrepancy between patients with or without thromboembolic events.Results In 107 patients, there were 65 female and 42 male patients, with mean age (39.8 ± 15.8) years old, median disease duration 10.5 (2.0, 48.0) months.A total of 72(67.3%) patients reported episodes of thromboembolic events, including 72 venous thromboses and 29 arterial thromboses.The most frequent venous thromboses were deep vein thromboses (35.5%), pulmonary embolism the second common (29.9%), with cranial venous sinus thromboses the following (8.4%).In arterial thromboembolic events, the incidence of transient ischemic attack (TIA) and ischemic stoke was the highest (14.0%), embolism of lower extremities the second (6.5%) ,and 4 patients (3.7%) with acute myocardial infarction.Sixty seven patients (62.6%)had positive lupus anticoagulant, 60 patients (56.1%)with positive anticardiolipin antibody,32 patients (29.9%, 32/74) with positive β2 glycoprotein Ⅰ (β2GP I).Forty patients(37.4%)had double positive antibodies, while 19 cases (17.8%)with triple positive.In logistical regression, aging (per 10 years) and hypocomplementemia were significantly related to venous thrombosis (OR =1.421, 95% CI 1.066-1.894, P < 0.05, and OR =6.435, 95% CI 1.374-30.130, P < 0.05, respectively).Cigarette smoking and triple positive antibodies were independent risk factors of arterial thrombosis (OR =3.996, 95% CI 1.079-14.795, P < 0.05 and OR =3.166, 95% CI 1.102-9.097, P < 0.05, respectively).Conclusion Alas is an autoimmune disorder characterized by recurrent arterial and venous thromboembolic events.Venous thromboembolism is more common than the arterial.Age and hypocomplementemia are predictors of venous thromboembolism;while smoking and triple positive antibodies are independent risk factors of arterial thromboembolism.
出处 《中华内科杂志》 CAS CSCD 北大核心 2016年第5期386-391,共6页 Chinese Journal of Internal Medicine
基金 国家高技术研究发展计划(863计划)(2012AA02A513):系统性红斑狼疮分子分型和个体化诊疗技术
关键词 抗磷脂综合征 血栓形成 抗磷脂抗体 低补体血症 抗凝 Antiphospholipid syndrome Thrombosis Antiphospholipid antibodies Hypocomplementemia Anticoagulation
  • 相关文献

参考文献22

  • 1Miyakis S, Loekshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [ J ]. J Thromb Haemost, 2006,4(2) :295-306.
  • 2Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [ J ]. Arthritis Rheum, 1997,40 (9) : 1725.
  • 3Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjtgren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group [ J] . Ann Rheum Dis, 2002,61 (6) :554-558.
  • 4Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[ J ]. Arthritis Rheum, 1988,31 ( 3 ) : 315- 324.
  • 5Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti- Domain I beta2 Glycoprotein I antibodies by chemil immunoassay in primary antiphosphohpld syndrome [ J ]. 11n Chim Acta, 2015,446:201-205.
  • 6Willis R, Grossi C, Orietta BM, et al. International standards for IgG and IgM anti-[32glyeoprotein antibody measurement [ J ]. Lupus ,2014,23 ( 12 ) : 1317-1319.
  • 7Pengo V. ISTH guidelines on lupus anticoagulant testing [ J ]. Thromb Res, 2012,130 Suppl 1 :$76-77.
  • 8Fujieda Y, Atsumi T, Amengual O, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome [ J ]. Lupus, 2012,21 ( 14 ) : 1506- 1514.
  • 9徐娜,张尧,张文,赵岩,曾小峰.抗磷脂综合征165例临床特征与分型[J].中华内科杂志,2009,48(11):904-907. 被引量:9
  • 10Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus : evaluation of 23 possible combinations of antiphospholipid antibody specificities [ J ]. J Thromb Haemost, 2012,10(12) :2512-2518.

二级参考文献15

  • 1Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Muhicenter Study of 114 patients. Am J Med, 1994,96:3-9.
  • 2Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum,2002, 46 : 1019-1027.
  • 3Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med ,2002,346:752-763.
  • 4Baker WF Jr, Bick RL, Fareed J. Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management. Hematol Oneol Clin North Am, 2008,22 : 155-174, viii.
  • 5Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( APS ). J Thromb Haemost, 2006,4 : 295 -306.
  • 6Asherson RA. New subsets of the antiphospholipid syndrome in 2006: " PRE-APS " ( probable APS ) and microangiopathic antiphospholipid syndromes (" MAPS" ). Autoimmun Rev, 2006, 6:76-80.
  • 7Baker WF Jr, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am,2008,22:33-52, v-vi.
  • 8Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis ,2003,62 : 1127.
  • 9Provenzale JM, Ortel TL, Allen NB. Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. A JR Am J Roentgenol, 1998,170:285-290.
  • 10Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev,2008, 22 : 187-194.

共引文献8

同被引文献127

引证文献30

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部